Biotech | February 22, 2022
Prestige BioPharma’s facility receives EU-GMP certification
The facility will manufacture its Herceptin biosimilar, Tuznue
The facility will manufacture its Herceptin biosimilar, Tuznue
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The sale is expected to close in the first quarter of 2022
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The grants are expected to be received over the next three years, commencing March 2022
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Subscribe To Our Newsletter & Stay Updated
